November 30, 2016 - By Dolores Ford
Expert analysts at Piper Jaffray’s equity research division decreased Arrowhead (ARWR)‘s stock rating from Overweight to Neutral on 30 November.
Out of 2 analysts covering Arrowhead (ARWR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15.0 is the highest target while $8.0 is the lowest. The $11.50 average target is 641.94% above today’s ($1.55) stock price. Arrowhead has been the topic of 2 analyst reports since August 18, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, November 10 by Chardan Capital Markets. The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) earned “Buy” rating by Cantor Fitzgerald on Thursday, August 18.
About 9.95M shares traded hands or 736.13% up from the average. Arrowhead Pharmaceuticals Inc (ARWR) has declined 26.09% since April 27, 2016 and is downtrending. It has underperformed by 31.32% the S&P500.
Analysts await Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report earnings on December, 12. They expect $-0.33 earnings per share, up 21.43% or $0.09 from last year’s $-0.42 per share. After $-0.32 actual earnings per share reported by Arrowhead Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 3.13% negative EPS growth.
Insitutional Activity: The institutional sentiment is 0 in 2016 Q2. Its the same as in 2016Q1. The ratio is the same, as 67 funds sold all Arrowhead Pharmaceuticals Inc shares owned while 0 reduced positions. only 0 funds bought stakes while 0 increased positions. They now own 6,170 shares or 99.97% less from 18.16 million shares in 2016Q1.
Great West Life Assurance Can has 5,700 shares for 0% of their US portfolio. Hanson Doremus Invest Mgmt, a Vermont-based fund reported 470 shares.
Insider Transactions: Since August 22, 2016, the stock had 0 insider purchases, and 1 insider sale for $160,000 net activity. Shares for $160,000 were sold by Myszkowski Kenneth Allen.
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The company has a market cap of $92.69 million. The Firm is engaged in developing RiboNucleic Acid interference therapeutics. It currently has negative earnings. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA.
According to Zacks Investment Research, “Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.”
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, incorporated on February 13, 2001, is a biopharmaceutical company. The Firm is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi therapeutics leverage this natural pathway of gene silencing to target and shut down specific disease causing genes. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. The Company’s ARC-520 is an RNAi therapeutic designed to treat chronic hepatitis B virus (HBV) infection by reducing the expression and release of new viral particles and viral proteins with the goal of achieving a functional cure for HBV. The Firm is conducting multiple Phase IIb clinical efficacy studies. The Company’s ARC-AAT is an unlocked nucleobase analog (UNA), which contains RNAi therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that can damage the liver and lungs of affected individuals. The Firm is conducting a Phase Ib clinical trial for ARC-AAT. The study is a multi-center, randomized, placebo-controlled, double blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels.
More notable recent Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) news were published by: Reuters.com which released: “Arrowhead Pharma sinks after shelving three drug programs” on November 30, 2016, also Fool.com with their article: “Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today” published on November 09, 2016, Fool.com published: “What’s Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?” on November 10, 2016. More interesting news about Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) were released by: Businesswire.com and their article: “Arrowhead Pharmaceuticals Announces Closing of License and Collaboration …” published on November 21, 2016 as well as Prnewswire.com‘s news article titled: “ARWR LOSS ALERT: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc …” with publication date: November 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford